AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20386073
Drug: Zidovudine 300
RxNorm normalized name: zidovudine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine 300 mg
Trial: 20386073
Drug: Amdoxovir plus
RxNorm normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amdoxovir plus Zidovudine 200 mg
Trial: 20386073
Drug: Amdoxovir plus
RxNorm normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amdoxovir plus Zidovudine 300 mg
Trial: 10099977
Drug: Low-dose step-up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose step-up FSH with IUI
Trial: 7380690
Drug: autologous reinfusion
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: autologous reinfusion of approximately 900 ml of freeze-preserved blood
Trial: 7380690
Drug: sham reinfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sham reinfusion of 50 ml of saline
Trial: 30190165
Drug: 20-mg TAK-063
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg TAK-063
Trial: 28284477
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei rhamnosus Lcr35 (8 × 108 colony‐forming units, n=48), twice daily for 4 weeks
Trial: 28284477
Drug: Placebo (n=46),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (n=46), twice daily for 4 weeks
Trial: 26352940
Drug: Paracetamol mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol mixed with a liquid meal administered by a nasogastric feeding tube
Trial: 26352940
Drug: Paracetamol mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol mixed with a liquid meal
Trial: 26352940
Drug: Paracetamol in
RxNorm normalized name: Lloydspharmacy Paracetamol Infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol in the aqueous phase of the meal
Trial: 26352940
Drug: Paracetamol in
RxNorm normalized name: Lloydspharmacy Paracetamol Infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol in the solid bolus of the meal
Trial: 26352940
Drug: Paracetamol as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol as a post prandial marker
Trial: 21259004
Drug: Atorvastatin 5
RxNorm normalized name: amlodipine-atorvastatin 5 mg-80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 5 mg/day (TS 1) and 10 mg/day (TS ≥ 2), with doses doubled at week 4 if LDL-C target not achieved, for 8 weeks
Trial: 21259004
Drug: Atorvastatin 5
RxNorm normalized name: amlodipine-atorvastatin 5 mg-80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 5 mg/day (TS 1) and 10 mg/day (TS ≥ 2), for 8 weeks
Trial: 21259004
Drug: Atorvastatin 5
RxNorm normalized name: amlodipine-atorvastatin 5 mg-80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 5 to 10 mg (TS 1) or 10 to 20 mg (TS ≥ 2) for 8 weeks
Trial: 11443562
Drug: Intravenous palivizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous palivizumab (15 mg/kg)
Trial: 11443562
Drug: Intravenous palivizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous palivizumab (15 mg/kg) with aerosolized ribavirin
Trial: 7963081
Drug: Sugar expectancy
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar expectancy condition (mothers told their children received a large dose of sugar)
Trial: 17138773
Drug: Eszopiclone 3
RxNorm normalized name: eszopiclone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eszopiclone 3 mg nightly for 4 weeks
Trial: 12955028
Drug: Sex steroid
RxNorm normalized name: Sex steroid binding globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex steroid treatment (testosterone for men, oestrogen/progestin for women)
Trial: 9200306
Drug: Interferon mono-therapy
RxNorm normalized name: tiotropium bromide mono
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon mono-therapy
Trial: 9200306
Drug: Interferon-ribavirin combination
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Interferon-ribavirin combination therapy
Trial: 9200306
Drug: Prolonged interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged interferon therapy
Trial: 3083211
Drug: 250 mg/d
RxNorm normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/d of sorbinil
Trial: 27431451
Drug: Bilateral arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral arm remote ischemic postconditioning (RIPC) twice a day for 6 months
Trial: 22804619
Drug: 20-G cannula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-G cannula
Trial: 22804619
Drug: 22-G cannula
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 22-G cannula
Trial: 21127697
Drug: Safflower seed
RxNorm normalized name: SAFFLOWER SEED
DrugBank: Safflower (DB10905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower seed extract (SSE) 70 mg/day for 12 weeks
Trial: 18492267
Drug: Daily interruption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interruption of sedation (DIS)
Trial: 10621928
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (5 mg/kg)
Trial: 27179184
Drug: Treatment-as-usual PRS
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual PRS (Control)
Trial: 22460438
Drug: Blastocyst group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blastocyst group (thawed and cultured in sequential media until blastocyst stage)
Trial: 19687336
Drug: PLD 30
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD 30 mg/m2 followed by docetaxel 60 mg/m2 every 21 days (n = 378)
Trial: 19687336
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 (n = 373)
Trial: 17578957
Drug: LMA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMA with propofol + 7.5 ng/mL remifentanil (LMA-PR)
Trial: 17578957
Drug: LT with
RxNorm normalized name: Ascorbic Acid/Bioflavonoid/Biotin/Calcium/Cholecalciferol/Choline/Copper/Eleutherococcus senticosus Root/Inositol/Iodine/Iron/L-Methylfolate Glucosamine/Lutein/Magnesium/Manganese/Methylcobalamin/Molybdenum/Niacin/Pantothenic Acid/Phytonadione/Pyridoxine/Riboflavin/Rutin/Selenium/Sodium/Thiamine/Vitamin A/Vitamin E/Zinc 300 MG-20 MG-11 MCG-108.3 MG-16.7 MCG-10 MG-0.3 MG-16.7 MG-16.7 MG-50 MCG-6 MG-139.3 MCG-166.7 MCG-43.3 MG-1.93 MG-26.7 MCG-15 MCG-33.3 MG-21 MG-40 MCG-6.67 MG-6.67 MG-8.3 MG-52.67 MCG-3.33 MG-6.67 MG-900 MCG-33.3 MG-3.67 MG Oral Tablet [ALIVE! MAX3 POTENCY ADULT WITH IRON]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT with propofol + 7.5 ng/mL remifentanil (LT-PR)
Trial: 18485457
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg lornoxicam
Trial: 11773166
Drug: Oxaliplatin 85
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85 mg/m² plus Irinotecan 175 mg/m²
Trial: 11773166
Drug: Raltitrexed 3
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed 3 mg/m²
Trial: 9419196
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg orally twice daily
Trial: 8127329
Drug: alpha‐tocopherol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐tocopherol (50 mg per day)
Trial: 8127329
Drug: beta carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta carotene (20 mg per day)
Trial: 2916913
Drug: Immediate postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate postoperative physical therapy
Trial: 8478756
Drug: No physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No physical therapy (Control)
Trial: 791329
Drug: labetalol 400
RxNorm normalized name: labetalol 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol 400 mg/d
Trial: 791329
Drug: labetalol 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol 800 mg/d
Trial: 30953546
Drug: Mastery learning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mastery learning and deliberate practice (ML + DP)
Trial: 17470884
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg x day(‐1) po, followed by 200 mg po bid for three days)
Trial: 9667264
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 every 4 weeks
Trial: 9667264
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2 weekly
Trial: 2645420
Drug: Intracorporeal papaverine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracorporeal papaverine (30 mg. per ml.)
Trial: 2645420
Drug: Intracorporeal prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracorporeal prostaglandin E1 (10 mcg. per ml.)
Trial: 31043808
Drug: Generic cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Generic cetuximab ($275.80 per 100 mg)
Trial: 28253845
Drug: Multimodal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal therapy (MT) consisting of sleep education/restriction, psycho-education, eurythmy- and painting-therapy
Trial: 28253845
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (CT) consisting of multimodal therapy (MT) plus aerobic training (AT)
Trial: 28253845
Drug: Standard aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard aerobic treatment (AT)
Trial: 26188537
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei Shirota (LcS) 6.5 × 10(9) CFU, 3 times daily for 12 weeks
Trial: 26188537
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (no LcS)
Trial: 10189455
Drug: Single-dose breath-hold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose breath-hold gadolinium-enhanced MR angiography with 20 mL of gadopentetate dimeglumine (average dose, 0.11 mmol/kg)
Trial: 2080949
Drug: Intravenous calcium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous calcium (9 mmol Calcium-Sandoz)
Trial: 396055
Drug: Praziquantel 1
RxNorm normalized name: praziquantel 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 1 x 20 mg/kg and 2 x 20 mg/kg
Trial: 28001151
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g per day of DSG for 14 days
Trial: 28001151
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g per day of DSG for 30 days
Trial: 28001151
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g per day of placebo for 30 days
Trial: 28001151
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g per day of DSG for both studies
Trial: 25648211
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones supplementation (33 g in the form of biscuits containing approximately 54 mg isoflavones for 8 weeks)
Trial: 21112195
Drug: 1.4% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4% gel
Trial: 19679843
Drug: Endothelin-receptor antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Endothelin-receptor antagonists (ETRAs)
Trial: 15329425
Drug: Fluconazole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (150 mg) weekly for six months
Trial: 15329425
Drug: Placebo weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo weekly for six months
Trial: 11336940
Drug: Unoprostone 0.12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unoprostone 0.12% twice daily
Trial: 7826846
Drug: VP‐16 and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VP‐16 and other drugs with leukemogenic effect in 17 patients
Trial: 7826846
Drug: Only drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only drugs with leukemogenic effect in 6 patients
Trial: 7826846
Drug: Other drugs
RxNorm normalized name: Other drugs for bile therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drugs in 35 patients
Trial: 30595329
Drug: Carvedilol 12.5
RxNorm normalized name: carvedilol 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 12.5 mg/day
Trial: 30595329
Drug: Carvedilol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (all doses combined)
Trial: 22397653
Drug: Pasireotide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 600 μg twice daily
Trial: 22397653
Drug: Pasireotide 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide 900 μg twice daily
Trial: 22397653
Drug: Pasireotide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide (both doses)
Trial: 20064692
Drug: Pentoxifylline (PTF)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTF) 1 mg ml(‐1)
Trial: 19368505
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine (PCV7) given 3 months after transplantation
Trial: 19368505
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine (PCV7) given 9 months after transplantation
Trial: 16418785
Drug: Alendronate (ALN),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN), 5-10 mg/day
Trial: 15288321
Drug: Azithromycin (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (4.0 g total over 4 weeks, 1000 mg weekly)
Trial: 15288321
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg b.i.d. for 28 days)
Trial: 8482456
Drug: Isosorbide-5-mononitrate (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (20 mg three times a day, n = 57)
Trial: 8482456
Drug: Propranolol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (up to maximum tolerated dose, n = 61)
Trial: 2446058
Drug: Ketanserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (20 or 40 mg doses twice daily)
Trial: 2446058
Drug: Ketanserin +
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin + Atenolol (100 mg/day)
Trial: 2446058
Drug: Ketanserin +
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin + Hydrochlorothiazide (50 mg/day) + Amiloride (5 mg/day)
Trial: 15963092
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate 400 mg once daily
Trial: 12906966
Drug: i.v.+s.c. enoxaparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v.+s.c. enoxaparin treatment
Trial: 12906966
Drug: s.c. alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. alone enoxaparin treatment
Trial: 7066128
Drug: Isobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric bupivacaine 7.5 mg ml‐1 administered in sitting position
Trial: 7066128
Drug: Isobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric bupivacaine 5 mg ml‐1 administered in horizontal position
Trial: 7066128
Drug: Isobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric bupivacaine 7.5 mg ml‐1 in horizontal posture
Trial: 7066128
Drug: Isobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric bupivacaine 5 mg ml‐1 in horizontal posture
Trial: 30260724
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of 0.5% levobupivacaine applied at incision sites + 10 mL 0.5% levobupivacaine injected intraperitoneally and at trocar sites
Trial: 30260724
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of 0.5% ropivacaine at incision sites + 10 mL 0.5% ropivacaine injected intraperitoneally and at trocar sites
Trial: 30260724
Drug: No peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No peritoneal or local administration of local anesthetics (Control Group 1)
Trial: 17560989
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy for cutaneous melanoma
Trial: 15729204
Drug: Immunotherapy approaches
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy approaches including antibodies, peptides, or dendritic cell vaccines
Trial: 9211625
Drug: Enoxaparin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (1 mg/kg s.c., bid and 1.5 mg/kg s.c. daily)
Trial: 8433421
Drug: Aspirin therapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin therapy (including enteric-coated aspirin and plain aspirin)
Trial: 31664303
Drug: Piroxicam (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (200 mg)
Trial: 25667217
Drug: Lidocaine 4%
RxNorm normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 4% (0.2 mL)
Trial: 25667217
Drug: Decongestant only
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestant only
Trial: 24967526
Drug: Drug Adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Adherence Work-up (DRAW) tool
Trial: 11681004
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy (combination therapy with mitomycin C, 5-fluorouracil, and nonspecific immunomodulators such as PSK and OK-432)
Trial: 11681004
Drug: Biochemical modulators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biochemical modulators (low-dose FP and S 1)
Trial: 7664193
Drug: Memory training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memory training (weekly group sessions of 60 min for 1 year)
Trial: 2718782
Drug: Calcium-25-OHD (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-25-OHD (1200 mg/day of calcium as calcium carbonate and 40 micrograms/day of 25-OHD)
Trial: 2718782
Drug: Calcium-placebo (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-placebo (1200 mg/day of calcium plus placebo)
Trial: 1097097
Drug: Daunorubicin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin (25 mg/m given intravenously) + Methotrexate (25 mg/m/dose given orally twice weekly)
Trial: 1097097
Drug: Methotrexate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (25 mg/m/dose given orally twice weekly)
Trial: 21375762
Drug: Chlorthalidone 12.5
RxNorm normalized name: chlorthalidone 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 12.5 mg plus amiloride 2.5 mg
Trial: 19713967
Drug: Active HHQ-reduced
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active HHQ-reduced coffee (300 mg chlorogenic acids per 184 ml of coffee)
Trial: 19713967
Drug: Placebo HHQ-reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo HHQ-reduced coffee (0 mg chlorogenic acids per 184 ml of coffee)
Trial: 17597089
Drug: ECC rinse
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ECC rinse with unfractionated heparin (UFH)
Trial: 17597089
Drug: ECC rinse
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ECC rinse without unfractionated heparin (UFH)
Trial: 8002117
Drug: Fluid ingestion
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid ingestion (F) - 400 ml bolus of 20 mmol/l NaCl immediately before exercise and 120 ml feedings every 10 min during the first 50 min of exercise.
Trial: 29212509
Drug: Low-dose, high-frequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose, high-frequency (LDHF) training
Trial: 25919644
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of finasteride (1.0 mg)